<DOC>
	<DOCNO>NCT01108848</DOCNO>
	<brief_summary>The objective patient registry collect data safety Berinert速 normal clinical practice United States . The patient registry maintain period least 3 year . The duration individual patient participation vary determine frequency hereditary angioedema ( HAE ) attack patient 's need Berinert速 treatment .</brief_summary>
	<brief_title>Patient Registry Study Berinert速 Normal Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<criteria>Any patient receiving CSL Behring 's C1esterase inhibitor Written inform consent ( may require retrospective chart review case ) Any patient participating HAE study use C1inhibitors Berinert速</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>C1-esterase Inhibitor</keyword>
	<keyword>Hereditary angioedema</keyword>
	<keyword>Acute HAE attack</keyword>
</DOC>